An Investigator Initiated Open-Label Controlled Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation.

Trial Profile

An Investigator Initiated Open-Label Controlled Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Alefacept (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 21 Oct 2010 Planned end date changed from 1 Jul 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 05 Oct 2009 Study design changed from open to double-blind, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top